No Data
Prescient Therapeutics Refines Phase 2 PTX-100 Trial Design for Greater Success
Prescient Therapeutics Appoints Accomplished Medical Professional Dr Gavin Shepherd as a Director
We're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash Wisely
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%
FDA Grants Prescient Therapeutics (ASX:PTX) Broad Orphan Drug Status for PTX-100 Cancer Treatment
Prescient Therapeutics (ASX:PTX) Shareholders Have Earned a 31% CAGR Over the Last Three Years
No Data
